This company has been acquired
Surface Oncology Past Earnings Performance
Past criteria checks 0/6
Surface Oncology's earnings have been declining at an average annual rate of -25.3%, while the Biotechs industry saw earnings growing at 23.5% annually. Revenues have been declining at an average rate of 11.1% per year.
Key information
-25.3%
Earnings growth rate
3.7%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -11.1% |
| Return on equity | -188.1% |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Recent updates
Forecast: Analysts Think Surface Oncology, Inc.'s (NASDAQ:SURF) Business Prospects Have Improved Drastically
Nov 07
Analysts Just Made A Major Revision To Their Surface Oncology, Inc. (NASDAQ:SURF) Revenue Forecasts
Aug 08Surface Oncology GAAP EPS of -$0.46 misses by $0.01
Aug 03Surface Oncology: Neither Novartis, Nor GSK Or ARKG Is Able To Stop The Decline
May 25News Flash: Analysts Just Made A Dazzling Upgrade To Their Surface Oncology, Inc. (NASDAQ:SURF) Forecasts
May 11Does Surface Oncology (NASDAQ:SURF) Have A Healthy Balance Sheet?
Feb 23Surface Oncology: If Novartis, GlaxoSmithKline And ARK See Promise, So Do I
Jan 18Is Surface Oncology (NASDAQ:SURF) A Risky Investment?
Nov 11Surface Oncology: Staying The Course
Oct 24Surface Oncology: A Diverse, But Early Pipeline
Jul 13Is Surface Oncology (NASDAQ:SURF) Using Too Much Debt?
Jun 07Surface Oncology EPS beats by $0.04, beats on revenue
May 05Here's What Surface Oncology, Inc.'s (NASDAQ:SURF) Shareholder Ownership Structure Looks Like
Mar 15Does Surface Oncology (NASDAQ:SURF) Have A Healthy Balance Sheet?
Feb 16
Surface Oncology: Early Stage Cancer-Specific Company With Novel Assets
Dec 09What Kind Of Shareholders Hold The Majority In Surface Oncology, Inc.'s (NASDAQ:SURF) Shares?
Dec 08Surface Oncology shares rise 13% on Fast Track tag for SRF388
Nov 11Revenue & Expenses BreakdownBeta
How Surface Oncology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 0 | -93 | 26 | -7 |
| 31 Mar 23 | 0 | -90 | 24 | 0 |
| 31 Dec 22 | 30 | -64 | 25 | 0 |
| 30 Sep 22 | 30 | -66 | 26 | 35 |
| 30 Jun 22 | 31 | -63 | 26 | 33 |
| 31 Mar 22 | 31 | -57 | 26 | 0 |
| 31 Dec 21 | 3 | -78 | 25 | 0 |
| 30 Sep 21 | 90 | 13 | 27 | 0 |
| 30 Jun 21 | 90 | 17 | 26 | 2 |
| 31 Mar 21 | 89 | 21 | 24 | 0 |
| 31 Dec 20 | 126 | 59 | 24 | 0 |
| 30 Sep 20 | 39 | -24 | 20 | 0 |
| 30 Jun 20 | 39 | -25 | 20 | 0 |
| 31 Mar 20 | 40 | -28 | 20 | 0 |
| 31 Dec 19 | 15 | -55 | 21 | 0 |
| 30 Sep 19 | 25 | -44 | 20 | 0 |
| 30 Jun 19 | 26 | -44 | 19 | 0 |
| 31 Mar 19 | 28 | -35 | 18 | 0 |
| 31 Dec 18 | 59 | -7 | 16 | 0 |
| 30 Sep 18 | 52 | -18 | 12 | 0 |
| 30 Jun 18 | 53 | -15 | 12 | 0 |
| 31 Mar 18 | 57 | -13 | 11 | 0 |
| 31 Dec 17 | 13 | -45 | 11 | 0 |
| 30 Sep 17 | 12 | -36 | 9 | 0 |
| 31 Dec 16 | 7 | -17 | 4 | 0 |
Quality Earnings: SURF is currently unprofitable.
Growing Profit Margin: SURF is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SURF is unprofitable, and losses have increased over the past 5 years at a rate of 25.3% per year.
Accelerating Growth: Unable to compare SURF's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SURF is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-33.7%).
Return on Equity
High ROE: SURF has a negative Return on Equity (-188.1%), as it is currently unprofitable.